This invention relates to pharmaceutical formulations of gemcitabine [phenyl benzoxy L alaninyl)] phosphate a monophosphate derivative of the well known oncology drug gemcitabine. In particular the invention relates to formulations which comprise a polar aprotic solvent preferably dimethyl acetamide (DMA). Formulations comprising these solvent provide therapeutically effective treatments of gemcitabine [phenyl benzoxy L alaninyl)] phosphate. The invention also relates to methods of using said formulations and kits comprising said formulations.